Disrupted-in-Schizophrenia-1 (DISC1) is a genetic risk factor for a wide range of major mental disorders, including schizophrenia, major depression, and bipolar disorders. Recent reports suggest a potential role of DISC1 in the pathogenesis of Alzheimer's disease (AD), by referring to an interaction between DISC1 and amyloid precursor protein (APP), and to an association of a single-nucleotide polymorphism in a DISC1 intron and late onset of AD. However, the function of DISC1 in AD remains unknown. In this study, decreased levels of DISC1 were observed in the cortex and hippocampus of 8-month-old APP/PS1 transgenic mice, an animal model of AD. Overexpression of DISC1 reduced, whereas knockdown of DISC1 increased protein levels, but not mRNA levels of β-site APP-Cleaving Enzyme 1 (BACE1), a key enzyme in amyloid-β (Aβ) generation. Reduction of BACE1 protein levels by overexpression of DISC1 was accompanied by an accelerating decline rate of BACE1, and was blocked by the lysosomal inhibitor chloroquine, rather than proteasome inhibitor MG-132. Moreover, overexpression of DISC1 in the hippocampus with an adeno-associated virus reduced the levels of BACE1, soluble Aβ40/42, amyloid plaque density, and rescued cognitive deficits of APP/PS1 transgenic mice. These results indicate that DISC1 attenuates Aβ generation and cognitive deficits of APP/PS1 transgenic mice through promoting lysosomal degradation of BACE1. Our findings provide new insights into the role of DISC1 in AD pathogenesis and link a potential function of DISC1 to the psychiatric symptoms of AD.
INTRODUCTION
The amyloid hypothesis of Alzheimer's disease (AD) maintains that the accumulation of amyloid-β (Aβ), especially its oligomeric forms, is a key event in disease pathogenesis (Masters and Beyreuther, 2006) . The generation of Aβ is initiated by the proteolytic cleavage of amyloid precursor protein (APP) by β-secretase, which generates β-CTF, a C-terminal membrane-retained fragment of APP. The latter is further cleaved by γ-secretase and thus produces Aβ (Masters and Beyreuther, 2006) . APP is also under sequential cleavage by α-secretase and γ-secretase, which precludes generation of Aβ (Sapra and Kim, 2009 ). Thus, β-secretase mediates the initial and rate-limiting processing step during Aβ generation. β-Site APP-cleaving enzyme 1 (BACE1), a type I transmembrane aspartyl protease, is the sole β-secretase in the brain. BACE1-deficient neurons do not produce detectable levels of Aβ40, Aβ42, or β-CTF, and AD mouse models with BACE1 deficiency do not generate amyloid deposition (Cai et al, 2001; Luo et al, 2001; Ohno et al, 2004) . Moreover, protein levels and enzymatic activity of BACE1 are both increased in the brains of AD patients (Holsinger et al, 2002; Johnston et al, 2005; Yang et al, 2003) . Therefore, inhibition of BACE1 is a potential therapeutic target for AD. Identification of molecules that reduce the increased levels/activity of BACE1 in the brains of AD patients may provide a worthwhile strategy in AD therapy.
Disrupted-in-Schizophrenia-1 (DISC1) is a genetic risk factor for a wide range of major mental disorders. Familial mutations in the DISC1 gene, including the balanced chromosomal (1; 11) (q42.1; q14.3) translocation, cosegregate with schizophrenia, major depression, and bipolar disorders (Schosser et al, 2010) . This chromosomal translocation generates a C-terminal truncated or a fusion protein with DISC1 or a haploinsufficient DISC1 protein, which all cause dysfunctions of DISC1 (Brandon and Sawa, 2011) . DISC1 has essential roles in nervous system development, such as proliferation and differentiation of neural progenitor cells (Duan et al, 2007; Ishizuka et al, 2011; Lee et al, 2011) , neuronal migration (Kamiya et al, 2005 (Kamiya et al, ,2008 Young-Pearse et al, 2010) , neurite outgrowth (Miyoshi et al, 2003; Ozeki et al, 2003) , synapse formation Kvajo et al, 2008; Lee et al, 2011) , and mitochondrial trafficking (Atkin et al, 2011; Park et al, 2010) . Interestingly, substantial evidence suggests that DISC1 is linked to AD. DISC1 interacts with APP (Young-Pearse et al, 2010) , from which Aβ is derived by proteolytic cleavage through a BACE1-dependent mechanism. A genome-wide association study indicates an association of a single-nucleotide polymorphism in a DISC1 intron and late onset of AD (Beecham et al, 2009) . However, the function of DISC1 in the pathogenesis of AD remains unknown. In our study, we observe decreased levels of DISC1 in the cortex and hippocampus of 8-month-old APP/ PS1 transgenic mice, which express a chimeric mouse/ human Swedish mutant APP (APPswe) and a mutant human presenilin 1 (PS1). We further provide evidence that DISC1 interacts with BACE1 and promotes lysosomal degradation of BACE1, thus reducing the generation of Aβ. Overexpression of DISC1 via an adeno-associated virus in the hippocampus reduces the levels of soluble Aβ40 and Aβ42, the density of Aβ plaques and, importantly, rescues cognitive deficits in APP/PS1 transgenic mice. Therefore, we propose that DISC1, a genetic risk factor for mental disorders, has essential roles in the pathology of AD.
MATERIALS AND METHODS

Mice
APP/PS1 transgenic mice (stock number 004462) were purchased from the Jackson Laboratory and maintained by breeding with C57BL/6 mice. Littermates, matched in gender, were used in all experiments. Animal care and surgical procedures were approved by the Animal Studies Committee of Southern Medical University and of the Beijing Military Hospital in accordance with the international laws.
Antibodies
Anti-BACE1 (D10E5, CST, Danvers, MA); anti-DISC1 (Invitrogen, Grand Island, New York; Santa Cruz, Dallas, Texas); anti-Aβ (6E10, Covance, Dedham, MA); antilysosomal-associated membrane protein 1 (LAMP1) antibody (Abcam, Cambridge, MA); anti-APP and CTF (A8717), anti-Flag, anti-hemagglutinin (HA), and anti-β-actin were from Sigma-Aldrich (St Louis, MI); Alexa Fluor-conjugated secondary antibodies were from Invitrogen; horseradish peroxidase (HRP)-conjugated secondary antibodies were from Sigma-Aldrich.
Plasmids and siRNAs
Human full-length DISC1 cDNA containing a C-terminuslinked Flag was cloned into a pAOV vector containing the EF1a promoter, in which the green fluorescent protein (GFP) insert was deleted. A pAOV vector-expressing GFP served as control. Human BACE1 cDNA containing a C-terminuslinked HA was cloned into the pcDNA3.1 vector. DISC1 siRNAs and standard normal control (NC) siRNA were from Genepharma (Shanghai, China). Human DISC1 siRNA (sense: 5′-GGCAGAUGGAUGACUUAGATT-3′; anti-sense: 5′-UCUAAGUCAUCCAUCUGCCTT-3′); mouse DISC1 siRNA (sense: 5′-GGCAAACACUGUGAAGUGCTT-3′, antisense: 5′-GCACUUCACAGUGUUUGCCTT-3′); and NC siRNA (sense: 5′-UUCUCCGAACGUGUCACGUTT-3′; anti-sense: 5′-ACGUGACACGUUCGGAGAATT-3′) were used.
Cell Culture and Transfection
CHO cells and HEK293 cells were cultured in Dulbecco's modified Eagle's medium (Invitrogen) supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine. Lipofectamin 2000 (Invitrogen) and Effectene (Qiagen, Hilden, Germany) were used for transfection according to the manufacturer's protocol. Primary neurons were cultured as described previously (Grunewald et al, 2012) . Cortical and hippocampal neurons were prepared from embryonic day 18 (E18) C57 mice. Transfection of siRNA in cultured neurons was performed using Amaxa Nucleofector (Lonza) according to the instructions provided by the manufacturer. Neurons were then seeded in to six-well plates pre-coated with poly-D-lysine (Sigma) and cultured in Neurobasal medium supplemented with 2% B-27, 2 mM Glutamax-1 for 2 days.
Drug Treatment
MG-132 (M7449), chloroquine (C6628), and cycloheximide (C7698) were from Sigma-Aldrich. For measuring the time course of BACE1 degradation, HEK293 cells were treated with 40 μg/ml cycloheximide at 18 h after transfection of either DISC1-Flag or GFP. Cells were harvested at 0, 8, and 16 h after addition of cycloheximide. Cell lysates were collected at different time points after treatment and were then subjected to western blot analysis. For inhibition of lysosomal functions, HEK293 cells transfected with either DISC1-Flag or GFP were treated for 36 h with 25 μM chloroquine or 0.5 μM MG-132, lysed, and subjected to western blot analysis.
Reverse Transcription-PCR
Total cellular and tissue RNA were extracted using Trizol Reagent (Sigma-Aldrich). Equal amount of the first-strand cDNAs was synthesized with the FastQuant RT Kit (Tiangen Biotech, Beijing, China). PCR reactions were performed with Taq DNA polymerase (Takara, Dalian, China). The following primers were used: Human BACE1: 5′-ACCAACC TTCGTTTGCCCAA-3′ (forward), 5′-TCTCCTAGCCAGA AACCATCAG-3′ (reverse); Mouse Bace1: 5′-GTCATGAAC GTAGCCCAGGT-3′ (forward), 5′-GAGAGGAATGTGA AGCCTCG-3′ (reverse); Human DISC1: 5′-GCACCCT-GAGGAAGAAAGTT-3′ (forward), 5′-TCTCTTCTCAGTC TGTTGTAATCT-3′ (reverse); Human GAPDH: 5′-TTGG TATCGTGGAAGGACTCA-3′ (forward), 5′-TGTCATCA TATTTGGCAGGTT-3′ (reverse). Mouse Gapdh: 5′-TCC ACCACCCTGTTGCTGTAG-3′ (forward), 5′-GACCACAG TCCATGACATCACT-3′ (reverse).
Western Blot Analysis
Brain tissue and cells were lysed in RIPA buffer (50 mM Tris buffer (pH 7.4), 150 mM NaCl, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS) containing 1 mM PMSF and 1 × Protease Inhibitor Cocktail. Lysates were subjected to Tricine-SDS-PAGE for detection of CTFs, or SDS-PAGE for other proteins, followed by transferring to a polyvinylidene fluoride membrane (Merck Millipore, Darmstadt, Germany). The membranes were blocked with 5% BSA in Tris-buffered saline, pH 7.3 (TBS) containing 0.05% Tween-20 (TBST) for 1 h, and then incubated with primary antibodies diluted in blocking buffer for overnight at 4°C. The membranes were washed with TBST and incubated with HRP-conjugated secondary antibodies (Sigma-Aldrich) for 2 h at room temperature. ECL Plus or ECL Advance Western Blotting Detection Reagents (Amersham Biosciences, Piscataway, NJ) were used to visualize the immunoreactive proteins. The intensities of the bands were quantified by Image J analysis (NIH, Bethesda).
Co-Immunoprecipitation
Mouse hippocampus and HEK293 cells were lysed with RIPA buffer containing the Protease Inhibitor Cocktail. The lysates were precleared with protein A/G plus agarose beads (Santa Cruz, Dallas) for 2 h and incubated together with antibody-conjugated beads overnight at 4°C. The beads were washed three times with RIPA buffer, re-suspended in SDS electrophoresis sample buffer, and boiled for 5 min at 95°C. Samples were subjected to SDS-PAGE and western blot analysis.
Virus Injection
Adeno-associated virus (serotype 8, AAV8) expressing human DISC1 or GFP were generated by Niuen Biotechnology (Shanghai, China). AAV8 viral particles (3.1 × 10 12 vector genome/ml) were injected bilaterally into the hippocampus (−2.1 mm anteroposterior from bregma, ± 1.8 mm mediolateral from bregma, and 1.8 mm below the surface of the skull) of 4-month-old APP/PS1 transgenic mice and gendermatched wild-type littermates (15 mice in each group) by a stereotaxic apparatus as described (Kiyota et al, 2010) . AAV8-expressing GFP only was injected as control. One microliter of the virus suspension was injected into each hippocampus of a mouse through a 25-μl gauge needle at the rate of 0.2 μl/min. After injection, the needle was left in place for an additional 5 min before being slowly withdrawn. Mice were subjected to behavioral tests 3.5 months later and then killed for analysis of amyloid plaque deposition and tissue levels of Aβ and BACE1.
Morris Water Maze
This test was performed as described . Briefly, mice were trained for 7 consecutive days, 4 trials per day. A different start location was used in each trial. Each trial lasted until the mice found the platform or for a 90 s. If the mice failed to find the platform in 90 s, they were gently guided to the platform and allowed to stay on the platform for 10 s. Escape latencies (time spent swimming from start point to the target) and path length (the distance from start point to the platform) before reaching the platform were recorded for 6 consecutive days. For the probe trial on day 7, the platform was removed. The numbers of times that the mice swam crossed the platform area were recorded during 60 s. In the reversal trial on day 8, the platform was moved to the opposite quadrant, and the mice received four training trials per day for 2 consecutive days. Escape latencies and the number of times that the mice swam across the platform area were recorded.
Immunofluorescence
Decapitated brains were immersed for fixation in 4% paraformaldehyde for 24 h followed by 30% sucrose in PBS, all at 4°C. Coronal sections, 15 μm in thickness, were cut in a cryostat. Sections were washed three times with PBS containing 0.3% Triton X-100 (PBST), 10 min each, followed by blocking with 10% BSA in PBS for 1 h, and incubated with primary antibody overnight at 4°C. Sections were washed three times in PBS and incubated with appropriate secondary Alexafluor-conjugated antibodies for 2 h at room temperature. The sections were then washed three times with PBS and mounted in mounting medium containing DAPI (Vector Laboratories, Burlingame). For immunocytochemistry, cells were fixed by 4% paraformaldehyde for 15 min. Cells were then washed and immersed for 0.1% Triton X-100 (PBST) for 5 min, followed by blocking with 10% BSA in PBS for 1 h, and incubated with primary antibody overnight at 4°C. Cells were washed and incubated with appropriate secondary Alexa Fluor-conjugated antibodies for 1 h at room temperature.
ELISA for Measuring Levels of Aβ
For quantitation of Aβ, tissues from the cortex or hippocampus were lysed with solution A (5 M guanidine HCl, 50 mM Tris HCl, pH 8.0) and kept at room temperature for 3 h. The lysates were then diluted with cold Reaction Buffer B (Dulbecco's phosphate-buffered saline, pH 7.4, containing 5% BSA, and 0.03% Tween-20) supplemented with Protease Inhibitor Cocktail to achieve optimal dilution, and centrifuged at 16 000 g for 20 min at 4°C. The supernatant was then subjected to ELISA using the Aβ40 and Aβ42 ELISA KIT (Invitrogen) following the manufacturer's instructions.
ELISA for Determining Proteins Interaction
BACE1 intracellular domain (a.a. 478-501) peptide was synthesized by China peptides Company (Shanghai, China). Purified recombinant DISC1 protein (transcript variant L) was purchased from Origene (Rockville, MD). 500 nM of BACE1 peptide (a.a. 478-501) in PBS was used for substrate coating in 96-well plates at 4°C for overnight. The wells that were coated with PBS as substrate were used as the control. Wells were washed with PBS and blocked with 4% BSA in PBS for 1 h. Different concentrations of recombinant DISC1 protein (0, 5, 50, 100 nM) were added to each well and incubated for 1 h at 37°C. Wells were then washed and incubated with mouse anti-DSIC1 antibody followed by incubation with HRP-conjugated goat anti-mouse IgG. OD values were read using the TMB system (Invitrogen).
Image Analysis and Aβ Plaque Quantification
Image analysis and Aβ plaque quantification were performed as described in Zhang et al (2014) . Six mice per group were analyzed. Four sections of 15 μm in thickness from the hippocampus and cortex of each mouse were collected. All analyses were performed in corresponding sections from the same brain region in each group. Numbers and area of Aβ plaques of hippocampus and cortex in each image were quantified by Image J. The density of Aβ plaques was expressed as numbers of Aβ plaques per section. The size of Aβ plaques was quantified as the area occupied by Aβ plaques divided by the total area of the cortex or hippocampus.
Analysis of Translocation of BACE1 in Lysososmes
CHO cells were co-transfected with BACE1-HA and either DISC1 plasmid or the empty vector. Cells were treated with 25 μM chloroquine for 5 h at 16 h after transfection. Cells were then immunostained for HA, DISC1, and LAMP1. Images were acquired with a Zeiss confocal microscope. Image analysis and algorithm generation were performed using the Image-Pro Plus 6.0 software (Media Cybemetics, Silver Spring, MD). The Pearson's correlation coefficient in each cell was calculated as previously described (Yu et al, 2006) .
Statistical Analysis
All statistical analyses were performed using SPSS20.0. Data are presented as mean ± SEM. Comparisons between two groups were made by independent samples t-test. Morris Water Maze data were measured by two-way repeatedmeasures ANOVA followed by the Fisher LSD test. po0.05 was considered as significance level for all analyses. *po0.05; **p o0.01; ***po0.001.
RESULTS
Decreased Levels of DISC1 in the Brains of APP/PS1 Transgenic Mice
To investigate the potential role of DISC1 in the pathogenesis of AD, the levels of DISC1 in the hippocampus and cortex of APP/PS1 transgenic mice were investigated. Decreased levels of DISC1 were detected in the hippocampus (Figure 1a and b) and cortex (Figure 1c and d) of APP/PS1 transgenic mice at 8 months of age, when the mice display AD-like pathology, such as high load of amyloid plaques, loss of dendritic spines, and deficits in learning and memory . In contrast, DISC1 exhibited identical levels in the hippocampus (Figure 1a and b) and cortex (Figure 1c and d) of APP/PS1 transgenic mice, in comparison to wild-type littermates, at 4 months of age, when the transgenic mice exhibit no cognitive deficits and harbor only a few amyloid plaques . These results indicate a downregulation of DISC1 in the APP/PS1 brains, which may indicate a link to the pathogenesis of AD.
DISC1 Decreases Protein Levels of BACE1
In contrast to DISC1, levels of BACE1 have been reported to be increased in the APP/PS1 transgenic mouse brains at 10 months of age (Bao et al, 2013; Liang et al, 2010) , suggesting a potential link between these two molecules. To Reduction of BACE1 by DISC1 inhibits Ab generation Q-S Deng et al further investigate the relationship between these two molecules, DISC1-Flag and BACE1-HA plasmids were cotransfected into HEK293 cells. The cells co-transfected with a plasmid expressing GFP and BACE1-HA plasmid were taken as control cells. Cell lysates were collected 48 h after transfection and subjected to western blot analysis with an antibody against HA (Figure 2a ). Protein levels of BACE1 were decreased in DISC1-transfected cells compared with (e and h) HEK293 cells (e) or primary cultured neurons derived from E18 mouse hippocampus (h) were transfected with DISC1 siRNA (siDISC1) or the scrambled siRNA (normal control, NC). The levels of BACE1 and DISC1 were probed with BACE1 and DISC1 antibodies by western blot analysis. Actin was used as loading control. (f, g, i and j) The levels of BACE1 and of DISC1 in NC-transfected cells were normalized to 1.0 for quantification of the relative levels of BACE1 (f and i) and of DISC1 (g and j) in DISC1-siRNA-transfected HEK293 cells (f and g) and DISC1-siRNAtransfected primary cultured hippocampal neurons (i and j). (k and m) The levels of BACE1 mRNA in HEK293 cells transfected with DISC1-Flag (k) or with DISC1-siRNA (siDISC1, m) were analyzed by reverse transcription-PCR. Actin was used as control. (l and n) The levels of BACE1 mRNA in the control cells were normalized to 1.0 for quantification of the relative levels of BACE1 mRNA. Data are presented as mean ± SEM. *po0.05; **po0.01; ***po0.001. Independent samples t-test. n = 3/group. GFP-transfected control cells (Figure 2a and b) . To further analyze whether DISC1 would downregulate endogenous BACE1 protein levels, HEK293 cells, which express BACE1 endogenously, were transfected with the DISC1-Flag plasmid, and then probed by western blot analysis with an antibody against BACE1 (Figure 2c ). The protein levels of BACE1 were decreased in DISC1-transfected cells compared with those in GFP-transfected cells (Figure 2c and d) . Thus, Figure 3 For caption please refer page 446.
Reduction of BACE1 by DISC1 inhibits Ab generation Q-S Deng et al overexpression of DISC1 reduces levels of BACE1 in cultured cells. For further analysis, small interference RNA (siRNA) targeting DISC1 was transfected into HEK293 cells (Figure  2e-g ) and primary cultured neurons derived from E18 mouse hippocampus and cortex (Figure 2h-j) , which led to the downregulation of DISC1 levels in HEK293 cells ( Figure  2e and g) and neurons (Figure 2h and j) . The results showed that knockdown of DISC1 with siRNA-DISC1 enhanced protein levels of BACE1 in both HEK293 cells (Figure 2e and f) and neurons (Figure 2h and i) . However, mRNA levels of BACE1 were similar in both DISC1-transfected (Figure 2k and l) and DISC1 siRNA-transfected HEK293 cells ( Figure  2m and n), compared with control cells. These results indicate that DISC1 reduces BACE1 protein levels in a posttranscriptional manner.
DISC1 Associates with BACE1
DISC1 acts as a cellular protein scaffold by interacting with various proteins and affects the function of different proteins (Bradshaw and Porteous, 2012) . We further investigated whether DISC1 associates with BACE1. HEK293 cells cotransfected with DISC1-Flag and BACE1-HA were immunostained for DISC1 and BACE1 with antibodies against Flag and HA, respectively. As previously described, BACE1 immunoreactivity is detectable in perinuclear regions, which likely represent the Golgi apparatus and endoplasmic reticulum (Yan et al, 2001 ). DISC1 exhibited a staining pattern similar to BACE1 and colocalized with BACE1 in the perinuclear regions (Figure 3a ). Co-immunoprecipitation was performed to investigate a potential interaction between these two molecules. Antibodies against HA (Figure 3b ), Flag (Figure 3c ) immunoprecipitated DISC1-Flag (Figure 3b) , and BACE1-HA (Figure 3c ), respectively, from HEK293 cells cotransfected with BACE1-HA and DISC1-Flag plasmids. Moreover, antibodies against BACE1 and DISC1 immunoprecipitated DISC1 and BACE1, respectively, from the lysates of adult mouse hippocampus (Figure 3d ). To further analyze whether BACE1 directly binds to DISC1, ELISA experiment was performed. Using synthetic peptide that comprises the intracellular domain of BACE1 (a.a. 478-501) as the substrate coat, we observed a concentration-dependent binding of puried recombinant DISC1 protein to BACE1 peptide but not to the control (Figure 3e) . Therefore, these results indicate that DISC1 binds to BACE1 in cells and the brains.
DISC1 Promotes Lysosomal Degradation of BACE1
As DISC1 decreases the levels of BACE1 in a posttranscriptional manner and that DISC1 associates with BACE1, we asked whether DISC1 may affect the degradation of BACE1. HEK293 cells were transfected with either DISC1-Flag or GFP plasmid. The transfected cells were treated with the protein synthesis inhibitor cycloheximide at 18 h after transfection, when no significantly decreased levels of BACE1 had been yet observed by transfection of DISC1-Flag. The cell lysates were collected at 0, 8, and 16 h after addition of cycloheximide and subjected to western blot analysis with the BACE1 antibody. Levels of BACE1 in DISC1-Flag-transfected HEK293 cells were decreased after being treated by cycloheximide for 8 or 16 h, compared with those in GFP-transfected cells (Figure 3f) . Normalization of BACE1 levels to 1.0 before cycloheximide treatment (0 h) in either DISC1-Flag or GFPtransfected cells were allowed to quantification of relative levels of BACE1 after addition of cycloheximide for 8 and 16 h (Figure 3g ). BACE1 levels in DISC1-transfected HEK293 cells declined at a faster rate compared with those in GFPtransfected cells (Figure 3g ). These results suggest that DISC1 promotes the degradation of BACE1 protein, which had been reported to occur via lysosomes (Koh et al, 2005) . To examine this possibility, HEK293 cells were transfected with either DISC1-Flag or GFP and treated with the lysosomal inhibitor chloroquine or the proteasome inhibitor MG-132 (Koh et al, 2005) immediately after transfecion (Figure 3h ). The downregulation of BACE1 levels by transfection with DISC-Flag was blocked by treatment with chloroquine, but not with MG-132 (Figure 3h and i) . These results indicate that DISC1 promotes degradation of BACE1 through lysosomes. Considering that DISC1 has a role in regulation of the intracellular trafficking of protein and the fact that BACE1 is trafficked between subcellular compartments, such as the trans-Golgi network (TGN), the cell surface, and endosomes, and is eventually degraded in the lysosome (Jiang et al, 2014; Vassar et al, 2009 ), we examined whether DISC1 promotes translocation of BACE1 to lysosomes. CHO cells co-transfected with BACE1-HA and DISC1 were immunostained for HA and LAMP1, the marker of the lysosome (Figure 3j ). BACE1 is degraded in the lysosome, which makes very few BACE1 be detected in the lysosome (Kandalepas et al, 2013; Koh et al, 2005) . Thus, in this , and HA, following treatment with chloroquine for 6 h to prevent lysosomal degradation of BACE1. (k) Analysis of the colocalization ratio between LAMP1 ± and BACE1-HA ± fluorescent signal. Data are presented as mean ± SEM. *po0.05; **po0.01; ***po0.01. Independent samples t-test or one way ANOVA. n = 3 or 4/group. experiment, we treated transfected CHO cells with chloroquine for 6 h to prevent lysosomal degradation of BACE1 before immnostaining. The results showed that enhanced colocalization ratio between BACE1 and LAMP1 in DISC1-transfected cells compared with that in vector-transfected control cells (Figure 3k ), indicating that overexpression of DISC1 promotes translocation of BACE1 into lysosomes.
Overexpression of DISC1 Reduces Expression of BACE1 in APP/PS1 Transgenic Mice DISC1 reduces BACE1 protein levels through promoting lysosomal degradation of BACE1 in cultured cells. We then further validated whether DISC1 regulates BACE1 expression in the mouse brain. We injected an adeno-associated virus (serotype 8, AAV8) encoding DISC1-Flag into the hippocampus of APP/PS1 transgenic mice at 4 months of age. AAV8 expressing GFP was injected as control (Figure 4a and  b) . The expression of DISC1 via the virus was shown in the hippocampus by immunostaining for Flag (Figure 4c ) 4 months after injection. Expression of DISC1 was further confirmed by western blot analysis (Figure 4d) . A band at 100 kDa corresponding to the expression of DISC1-Flag in the hippocampus was detected by Flag antibody (Figure 4d) . Consistent with the results from cultured HEK293 cells, levels of BACE1 decreased in DISC1-AAV8-injected, compared with those in GFP-AAV8-injected hippocampus (Figure 4d and e). In contrast, BACE1 mRNA levels were similar in DISC1-Flag-AAV8-injected and GFP-AAV8-injected hippocampus (Figure 4f and g ). These results indicate that overexpression of DISC1 reduces the levels of BACE1 protein in the brain.
Overexpression of DISC1 Reduces Cleavage of APP by BACE1 in APP/PS1 Transgenic Mice
As DISC1 promotes the degradation of BACE1, which is the β-secretase in the brain, we investigated whether overexpression of DISC1 in the hippocampus would affect the cleavage of APP by BACE1 and thus generation of Aβ. Expression of β-or α-CTF, the C-terminal fragment of APP after being cleaved by BACE1 or α-secretase, respectively, were examined by western blot with an antibody against the intracellular domain of APP. β-CTF exhibited decreased levels in the hippocampus of DISC1-AAV8-injected APP/ PS1 transgenic mice at 8 months of age, ie, 4 months after injection of virus, in comparison to transgenic mice injected with GFP-AAV8 (Figure 4h and i) . In contrast, α-CTF (Figure 4h and j) and full-length APP (Figure 4h and k) were found at similar levels in the hippocampus of DISC-injected and GFP-injected APP/PS1 mice. These results indicate that DISC1 decreases the cleavage of APP by BACE1 rather than by α-secretase.
Overexpression of DISC1 Reduces the Density of Amyloid Plaques in APP/PS1 Transgenic Mice
Consistent with the results that DISC1 decreases BACE1-cleavage of APP, a key step for Aβ generation, decreased levels of soluble Aβ40 (Figure 5a ), and Aβ42 ( Figure 5b) were detected by ELISA in the hippocampus, but not in the cortex of DISC1-injected APP/PS1 mice. The ratio of Aβ40/Aβ42 levels were similar in the hippocampus of DISC1-injected and GFP-injected APP/PS1 mice (Figure 5c ), suggesting that DISC1 may have minimal effect on γ-secretase cleavage of CTFs (Yin et al, 2007) . Moreover, amyloid plaques exhibited reduced numbers (Figure 5d , e, g and h) and smaller size (Figure 5d , f, g and i) in the hippocampus (Figure 5d and f) , but not in the cortex (Figure 5g and i) , of DISC1-injected compared with those in GFP-injected APP/PS1 transgenic mice. These results indicate that overexpression of DISC1 reduces the generation of Aβ and thus the density of amyloid plaques in APP/PS1 transgenic mice.
Overexpression of DISC1 Rescues Cognitive Deficits of APP/PS1 Transgenic Mice
As overexpression of DISC1 decreases the density of amyloid plaques, which cause cognitive deficits in APP/PS1 transgenic mice, we examined whether overexpression of DISC1 would rescue the deficits in learning and memory of these mice. AAV8 encoding either DISC1-Flag or GFP was injected into the hippocampus of 4-month-old transgenic mice, which were then subjected to Morris water maze test 3.5 months after virus injection. Wild-type littermates injected into the hippocampus with AAV8 encoding GFP were used as controls. As described , GFPinjected transgenic mice were impaired in learning to use the available visuospatial cues to locate the submerged platform, as indicated by their longer escape latency compared with AAV8-GFP-injected wild-type mice (Figure 5j ). As expected, the escape latency of DISC1-injected transgenic mice was reduced compared with that of GFP-injected transgenic mice, and even approached a level comparable to GFP-injected wild-type mice (Figure 5j ). The changes in escape latency were not due to the differences in swimming speed, which were identical in the groups (Figure 5k) . Consistently, DISC1-overexpressing transgenic mice exhibited shorter swimming paths to locate the target, when compared with GFP-injected transgenic mice (Figure 5l and m) . After removal of the platform, although there is no statistic difference, a trend of increased number of times that DISC1-overexpressing transgenic mice swam across the platform area was observed, compared with that in GFP-injected transgenic mice (Figure 5n ). In the reversal trials, where the platform was moved to the opposite quadrant, DISC1-injected transgenic mice also exhibited shorter escape latencie (Figure 5o ) and increased number of times that swam cross the platform area (Figure 5p ), which are comparable to those of GFP-injected wild-type mice. These results indicate that overexpression of DISC1 in the hippocampus rescues cognitive deficits of APP/ PS1 transgenic mice.
DISCUSSION
DISC1 is well known as a genetic risk factor for mental disorders, such as schizophrenia, major depression, and bipolar disorder. The present study reveals a novel role of DISC1 in AD involving an interaction with BACE1. DISC1 reduces the stability of BACE1 through interaction with BACE1 in a lysosome-dependent mechanism. DISC1 has been reported involved in modulation of the stability of serine racemase (SR) by promoting the ubiquitinationdependent degradation in the proteasome in astrocytes (Ma et al, 2013) . However, the effect of DISC1 on the stability of SR is astrocyte specific. SR levels remain unchanged in DISC1 mutant neurons (Ma et al, 2013) . BACE1 is predominantly expressed in neurons rather than in astrocytes (Vassar et al, 1999) . These results suggest that DISC1 modulates the stability of certain proteins through different mechanisms in neurons and astrocytes. DISC1 acts as a cellular protein scaffold by interacting with and affecting the function of different proteins at different locations and times in development (Bradshaw and Porteous, 2012) . For example, DISC1 interacts with APP and reduces expression of APP on the cell surface via enhancing the internalization of APP (Shahani et al, 2015; Figure 5q ). DISC1 interacts with BACE1, which is trafficked between subcellular compartments, such as the TGN, the cell surface, and endosomes to be eventually degraded in the lysosome (Jiang et al, 2014; Vassar et al, 2009) , and promotes translocation of BACE1 to lysosomes, and thus accelerates its degradation (Figure 5q) . DISC1 shows reduced levels in APP/PS1 brains and promotes BACE1 degradation, being in agreement with the observations on elevated levels of BACE1 in the brains of AD patients (Holsinger et al, 2002; Johnston et al, 2005; Yang et al, 2003) and APP/PS1 transgenic mice (Bao et al, 2013; Liang et al, 2010) . It remains to be shown whether reduced expression of DISC1 occurs in the brains of AD patients and whether such a reduction would be correlated with levels of BACE1. However, it should be noted that BACE1 regulates the transcription of a subtype of DISC1 through cleavage of neuregulin, which binds to ErB4 after being cleaved Reduction of BACE1 by DISC1 inhibits Ab generation Q-S Deng et al . Thus, a feedback loop appears to exist between BACE1 and DISC1. Overexpression of DISC1 reduces protein levels of BACE1, whereas the reduction of BACE1 levels diminishes DISC1 transcription. Such a feedback loop may be a complementary mechanism in the maintenance of physiological expression of DISC1 and BACE1 in the brain. However, it is still unknown which factors disrupt such balance that eventually leads to reduced expression of DISC1 protein in the presence of elevated levels of BACE1. Further investigation on mRNA levels of DISC1 or epigenetic regulation of DISC1 in the brains of both AD patients and AD transgenic mice at different pathologic stages may help to answer this question.
A recent study has reported that knockdown or knockout of DISC1 inhibits Aβ generation through promoting expression of APP on the cell surface (Shahani et al, 2015) , where α-secretase primarily resides (Sisodia, 1992) . In contrast, we have observed in the present study that overexpression of DISC1 inhibits Aβ generation through reducing levels of BACE1, which tends to be catalytically active in the environment of the TGN or endosomal-lysosomal compartments (Sathya et al, 2012) . Both studies have observed that DISC1 does not change the levels of full-length APP. It is thus possible that enough full-length APP is available for being cleaved by BACE1, whereas some portion of APP remains on the cell surface undergoing α-secretase cleavage. This idea is consistent with the fact that levels of β-CTF are decreased by overexpression of DISC1 in the hippocampus of APP/PS1 transgenic mice as shown in the present study and are enhanced by knockdown or knockout of DISC1 as revealed by the shown western blots in a previous study (Shahani et al, 2015) . Levels of α-CTF are shown as a trend of decrease, but not statistically, by overexpression of DISC1 in this study and are increased significantly by knockdown or knockout of DISC1 in finding of (Shahani et al (2015) . Considering that β-CTF could be cleaved by α-secretase on the cell surface (Jager et al, 2009) , the cleavage of APP by α-and β-secretase might not always inversely correlate with each other as originally thought (Colombo et al, 2013; Wang et al, 2013) . Therefore, it is possible that DISC1 reduces both α-and β-secretase cleavage of APP via increasing internalization of APP and promoting lysosomal degradation of BACE1, respectively.
It has been suggested that wild-type APP (APPwt) and Swedish mutant APP (APPswe) utilize different cellular mechanisms for Aβ generation. β-Secretase cleavage of APPwt occurs in endocytic compartments after internalization from the cell surface (Jager et al, 2009) , whereas β-secretase cleavage of APPswe occurs late in the secretory pathway, which is almost independent of a functional internalization signal (Citron et al, 1992 Haass et al, 1995; Thinakaran et al, 1996; Jager et al, 2009) . In this study, overexpression of DISC1 reduces Aβ generation in APP/PS1 transgenic mice that harbor APP Swedish mutations (APP695 K595N/M596L) and a human PS1 mutation (deletion of exon 9) (Reiserer et al, 2007) . Thus, on the one hand, the APPswe mutation provides a preference of cleavage of APP by β-secretase (Citron et al, 1992) . On the other hand, β-secretase cleavage of APPswe is independent of APP internalization, whereas internalization of endogenous APPwt is increased by overexpression of DISC1 (Citron et al, 1992 Shahani et al, 2015) . These combined observations suggest that BACE1, rather than α-secretase, is the predominant secretase that cleaves APP in the hippocampus of APP/PS1 transgenic mice overexpressing DISC1. Thus, in this case, overexpression of DISC1 reduces Aβ generation in the presence of reduced levels of BACE1. Knockdown of DISC1 increases cell surface expression of APPwt by preventing its internalization (Shahani et al, 2015) . APP and α/β-CTF share a NPTY motif in the cytoplasmic domain, which represents a consensus sequence for the internalization of transmembrane cell surface proteins (Chen et al, 1990; Jager et al, 2009) . It is therefore possible that knockdown of DISC1 promotes cell surface expression of both full-length APP and α/β-CTF, which may reduce Aβ generation with the view that β-CTF at the cell surface could be further cleaved by α-secretase (Jager et al, 2009) . Thus, the discrepancy in Aβ generation between our study and study by Shahani et al. may due to the different extents in dependency on internalization by BACE1-cleavage of APPwt and APPswe and the methodological differences in overexpression and knockdown system. The paradoxical finding in Aβ generation in this study and in study Shahani et al (2015) is also consistent with that high BACE1 overexpression in an AD transgenic model decreases Aβ generation and thus the density of amyloid plaques, whereas moderate or low BACE1 overexpression increases Aβ generation (Lee et al, 2005) . Thus, more investigation, eg, overexpression of DISC1 in distinct AD mouse models or crossbreeding DISC1 knockout mice with APP/PS1 transgenic mice, will help to address this question.
It is noteworthy that the observations on reduction of Aβ generation by overexpression of DISC1 in the hippocampus are paralleled by the rescue of cognitive deficits of APP/PS1 transgenic mice, indicating that amelioration of plaque generation via DISC1 reducing levels of the Aβ-generating enzyme BACE1 ameliorates cognitive deficits in an animal Interaction of DISC1 and APP promotes endocytosis of APP to the endosome, and thus enhances Aβ generation. Whereas binding of DISC1 to BACE1 promotes translocation of BACE1 to the lysosome, and thus accelerates its degradation. Data are presented as mean+SEM. *po0.05; ***po0.001. Independent samples t-test (a-i). n = 6/group (a-i). Two-way repeated-measures ANOVA followed by the Fisher LSD test (j-p). n = 6-13/group (j-p). model of AD. These observations further highlight that downregulation of DISC1 expression may causally contribute to cognitive deficits of APP/PS1 mice. Consistently, mice expressing mutant DISC1 show deficits in working memory and short-term synaptic plasticity (Koike et al, 2006; Kvajo et al, 2008 Kvajo et al, , 2011 . Both APP and BACE1, two binding partners of DISC1 (Young-Pearse et al, 2010) , modulate synaptic plasticity (Filser et al, 2015; Petrus and Lee, 2014) . In contrast to that DISC1 promotes internalization of APP from the cell surface (Shahani et al, 2015) , APP also shows a role in promoting the location of DISC1 in the centrosome (Young-Pearse et al, 2010) , and thus regulates neuronal migration, a process essential in maintenance of synaptic plasticity in the brain. It has been reported that regulation of neuronal migration by APP requires full-length APP (Young-Pearse et al, 2010) . Our study shows that DISC1 in the cytoplasm accelerates degradation of BACE1 through promoting its translocation in the lysosome. Thus, it is possible that decreased levels of DISC1 enhances the cleavage of APP by BACE1 and thus decreases the levels of full-length APP, which is required in regulation of neuronal migration. However, it requires more experiments to address this possibility. It also requires further investigation on whether such process contributes to cognitive deficits of APP/PS1 mice independent on Aβ.
Moreover, several neuropsychiatric symptoms, such as abnormalities in emotionality/activity, social interactions, and sensomotor abilities are commonly detected in AD patients (Lyketsos et al, 2011) . Deficits in working memory and social interactions that have been described for DISC1 mutant mice (Ayhan et al, 2011; Koike et al, 2006; Pletnikov et al, 2008) are also observed in BACE1 knock-in transgenic mice (Plucinska et al, 2014) . Thus, the present study may suggest a possibility that decreased levels of DISC1 may account for the neuropsychiatric symptoms in AD. Investigations of DISC1 in relation to the neuropsychiatric symptoms of AD will not only suggest a basis for understanding these aspects of AD, but hopefully also help to understand some aspects of other mental diseases.
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